4//SEC Filing
Nagendran Sukumar 4
Accession 0001415889-25-022750
CIK 0001806310other
Filed
Aug 21, 8:00 PM ET
Accepted
Aug 22, 4:15 PM ET
Size
5.4 KB
Accession
0001415889-25-022750
Insider Transaction Report
Form 4
Nagendran Sukumar
DirectorPresident and Head of R&D
Transactions
- Sale
Common Stock
2025-08-21$2.85/sh−57,054$162,604→ 1,165,289 total
Footnotes (2)
- [F1]Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001665124
Filing Metadata
- Form type
- 4
- Filed
- Aug 21, 8:00 PM ET
- Accepted
- Aug 22, 4:15 PM ET
- Size
- 5.4 KB